Regenerative Medicine and Stem Cells Technologies

The Comprehensive Center for Stem Cells and Regenerative Medicine of Tehran University of Medical Sciences, with the establishment of accelerators, innovative cores, specialized laboratories and the provision of educational services, provides the ground for the development of technologies, commercialization of products and services in this field. In this center, 5 reconstructive medicine accelerators are located.

Sorena Sattari, Vice President for Science and Technology, said at the inauguration ceremony of the collection of accelerators, clean rooms and the unveiling of the knowledge-based products of the Comprehensive Center for Stem Cells and Regenerative Medicine, referring to our country's progress in this field with the creativity of educated youth. It serves as a model for other universities to support academics' innovative ideas and move in that direction.

Sattari, referring to the role of universities in turning innovative ideas into products or services of scholars, added: "Universities can develop the environment of innovation and pave the way for progress by helping to produce products from the ideas of academics." Fortunately, this ecosystem has reached significant growth and maturity in the field of stem cells.

The Vice President for Science and Technology, stating that the centers of innovation and business accelerators are the birthplace of knowledge-based and wealth-creating products, continued: "With the help of these centers, which are the birthplace of companies, young people with innovative ideas They themselves achieve employment and added value and, while meeting the needs of society, benefit the university.

The head of the Stem Cell Science and Technology Development Headquarters and Regenerative Medicine, referring to the production of Iranian knowledge-based products in the treatment of cancer, added: "A great deal of work has been done in the field of cancer treatment. And if successful in the human phase, it will enter the market.

Sattari spoke about the production of this knowledge-based product for the first time in the country, in step with the few developed countries active in this field, and continued: Gives and by eliminating the need for imports, the country saves the country's capital and creates a change in the treatment of cancer patients.

Referring to the important role of accelerators and private sector investors in generating revenue from innovative ideas, he said: "More than 200 knowledge-based companies out of more than 5,700 knowledge-based companies in the country are active in the field of stem cells and reconstructive medicine." The fact that many of the country's technological priorities in various fields are met by knowledge-based companies shows the position and importance of these businesses.

Sattari pointed to the unveiling of more than 30 new and advanced medical knowledge-based products at the event, adding: "Some of the products unveiled in the world are new or have not even been commercialized." Great work has been done with the production of these technological products, and the creation of this ecosystem in and around the university to create great changes is valuable and appreciated.

The head of the National Elite Foundation called these companies a platform for attracting top talents and non-resident Iranian elites and said: "These centers are a platform for attracting elites." Even now, a number of returning elites are pursuing the commercialization of their innovative idea or product in the accelerators of this innovation center. Soon, with the entry of these products into the market, we will see serious developments in the field of medicine and health.

In the continuation of this ceremony, while unveiling a clean room and a set of accelerators of the comprehensive center of stem cells from the established Danesbonyan products, it was inaugurated.

Solutions used in the treatment of infertility, synthesis of cytotoxicity assays, magnetic nanoparticle-based DNA and RNA extraction kits, and the first robotic nucleic acid products were among Dashbanian products unveiled at the Comprehensive Center for Stem Cells and Regenerative Medicine.

Also in another part of the ceremony, Abbas Ali Karimi, President of Tehran University of Medical Sciences, referring to the activities of technology and academic activists in the production of advanced knowledge-based products, said: University of Medical Sciences takes steps to produce knowledge-based products and technology Address the most important technological needs and priorities of the country.

He also said: "The work of the Vice President for Science and Technology and the high motivation of the Vice President for Science and Technology in supporting innovative ideas and knowledge-based has been very effective and efficient."

One of the Iranian manufacturing technologies unveiled at the Comprehensive Stem Cell Center, T cell therapy work technology, which has been localized by Kara Yakhteh Equipping Company, has entered the phase of animal studies. This Iranian-made product is produced in Clean Room, the comprehensive center of stem cells. Kara Yakhteh Tajhiz Azma Company has been established in the Comprehensive Stem Cell Center since 1998 and has started a clinical trial in this center with the support of the Stem Cell Technology Development Headquarters of the Vice President for Science and Technology.

T-cell therapy is a method in which the treatment is based on the cells of the patient's body and the production of antibodies. Engineered and tampered cells are implanted in patients' bodies and act with great precision against cancer cells.

The turnover of this field is about $ 8.3 billion and 90 companies and 160 centers in the United States provide case cell technology for cell therapy, and Iran's success in obtaining this Iranian-made product puts our country among the few holders of T cell therapy technology. The results of the animal phase have been effective and have shown positive results in the treatment of cancer mice.

This product is made in Iran with the investment of 85 billion Tomans of the private sector, and if produced, it will reduce patient costs and prevent the outflow of currency.